Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial
Epilepsia · 2023-11 · 64 (11) · 2934-2946
DOI: 10.1111/epi.17754 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Epilepsia, online erschienen am 05.09.2023. Verfasst von Lieven Lagae und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Development and Regeneration, Pediatric Neurology Section, University Hospitals Katholieke Universiteit Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Objective
This study was undertaken to evaluate the long‐term safety, tolerability, and efficacy of adjunctive brivaracetam (BRV) treatment in pediatric patients with epilepsy.
Methods
A phase 3, open‐label, multicenter, long‐term follow‐up trial (N01266; NCT01364597) was conducted on patients (aged 1 month to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Development and Regeneration, Pediatric Neurology Section, University Hospitals Katholieke Universiteit Leuven, Leuven, Belgium.
- Department of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Freiburg, Germany.
- Department of Neuropediatrics, Bethesda Children's Hospital, Budapest, Hungary.
- UCB Pharma, Monheim am Rhein, Germany.
- UCB Pharma, Morrisville, North Carolina, USA.
- Department of Neurology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York, USA.
ORCID-Profile: Lieven Lagae, Kerstin Alexandra Klotz, András Fogarasi, Christoph Reichel, Harriet Kang
Förderung
- UCB Pharma
Zitieren
APA
Lagae, L., Klotz, K. A., Fogarasi, A., Floricel, F., Reichel, C., Elshoff, J. P., Fleyshman, S., & Kang, H. (2023). Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial. Epilepsia, 64(11), 2934-2946. https://doi.org/10.1111/epi.17754
Vancouver
Lagae L, Klotz KA, Fogarasi A, Floricel F, Reichel C, Elshoff JP, et al. Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial. Epilepsia. 2023;64(11):2934-2946. doi:10.1111/epi.17754
BibTeX
@article{Lagae2023,
author = {Lagae, Lieven and Klotz, Kerstin Alexandra and Fogarasi, András and Floricel, Florin and Reichel, Christoph and Elshoff, Jan-Peer and Fleyshman, Sofia and Kang, Harriet},
title = {Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open‐label, follow‐up trial},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {11},
pages = {2934--2946},
doi = {10.1111/epi.17754}
}
EUVIMED